MK-212

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
MK-212
Accession Number
DB12111
Type
Small Molecule
Groups
Investigational
Description

MK-212 has been used in trials studying the treatment of Alcoholism.

Structure
Thumb
Synonyms
  • CPP
External IDs
NSC-317326
Product Ingredients
IngredientUNIICASInChI Key
MK-212 hydrochloride8722D514RX61655-58-1PFIZGLUIYAZQFU-UHFFFAOYSA-N
Categories
UNII
62C3N7238U
CAS number
64022-27-1
Weight
Average: 198.65
Monoisotopic: 198.0672241
Chemical Formula
C8H11ClN4
InChI Key
CJAWPFJGFFNXQI-UHFFFAOYSA-N
InChI
InChI=1S/C8H11ClN4/c9-7-5-11-6-8(12-7)13-3-1-10-2-4-13/h5-6,10H,1-4H2
IUPAC Name
2-chloro-6-(piperazin-1-yl)pyrazine
SMILES
ClC1=NC(=CN=C1)N1CCNCC1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
(R)-warfarinThe risk or severity of adverse effects can be increased when MK-212 is combined with (R)-warfarin.
(S)-WarfarinThe risk or severity of adverse effects can be increased when MK-212 is combined with (S)-Warfarin.
2,5-Dimethoxy-4-ethylamphetamineThe risk or severity of serotonin syndrome can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with MK-212.
2,5-Dimethoxy-4-ethylthioamphetamineThe risk or severity of adverse effects can be increased when MK-212 is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.
4-Bromo-2,5-dimethoxyamphetamineThe risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with MK-212.
4-Bromo-2,5-dimethoxyphenethylamineThe risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyphenethylamine is combined with MK-212.
4-hydroxycoumarinThe risk or severity of adverse effects can be increased when MK-212 is combined with 4-hydroxycoumarin.
4-MethoxyamphetamineThe risk or severity of adverse effects can be increased when 4-Methoxyamphetamine is combined with MK-212.
5-methoxy-N,N-dimethyltryptamineThe risk or severity of adverse effects can be increased when MK-212 is combined with 5-methoxy-N,N-dimethyltryptamine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with MK-212.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
107992
PubChem Substance
347828412
ChemSpider
97104
BindingDB
50017452
ChEBI
92360
ChEMBL
CHEMBL269521
Wikipedia
MK-212

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentThrombocytopenias1
2CompletedTreatmentAlcohol Dependence1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.03 mg/mLALOGPS
logP0.97ALOGPS
logP0.53ChemAxon
logS-2.3ALOGPS
pKa (Strongest Basic)8.73ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area41.05 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity53.11 m3·mol-1ChemAxon
Polarizability19.72 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as n-arylpiperazines. These are organic compounds containing a piperazine ring where the nitrogen ring atom carries an aryl group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazinanes
Sub Class
Piperazines
Direct Parent
N-arylpiperazines
Alternative Parents
Dialkylarylamines / Aminopyrazines / Imidolactams / Aryl chlorides / Heteroaromatic compounds / Dialkylamines / Azacyclic compounds / Organopnictogen compounds / Organochlorides / Hydrocarbon derivatives
Substituents
N-arylpiperazine / Dialkylarylamine / Aminopyrazine / Aryl chloride / Aryl halide / Pyrazine / Imidolactam / Heteroaromatic compound / Secondary amine / Secondary aliphatic amine
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 15:22 / Updated on June 04, 2019 07:32